Product Description
Tizanidine is an FDA-approved drug for managing spasticity. It is a centrally acting alpha-2 receptor agonist. Tizanidine effectively works spasticity caused by multiple sclerosis, an acquired brain injury, or a spinal cord injury. It has also been shown to be clinically effective in managing patients suffering from chronic neck and lumbosacral neuralgia with a myofascial component to their pain and regional musculoskeletal pain syndromes. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30137790/)
Mechanisms of Action: ADRA2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Migraine Disorders|Migraine with Aura|Migraine without Aura
Phase 1: Muscle Spasticity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05484349 | P3 |
Recruiting |
Migraine with Aura|Migraine Disorders|Migraine without Aura |
2025-12-25 |
|
| ACTRN12624001134516 | P1 |
Not yet recruiting |
Muscle Spasticity |
None |